Bharat Biotech unveils next-gen oral cholera vaccine
Hyderabad: Pharma major Bharat Biotech has announced the launch of an oral cholera vaccine (OCV) developed under licence from Singapore-based Hilleman Laboratories to help combat cholera which continues to pose a significant global public health challenge, especially in regions with inadequate sanitation.
HILLCHOL (BBV131), a novel single-strain vaccine is to be administered orally on day 0 and day 14. It is suitable for babies older than one year.
According to IANS, in a statement, Bharat Biotech said that large-scale manufacturing facilities have been established in Hyderabad and Bhubaneswar with a capacity to produce up to 200 million doses.
“Vaccines provide the best intervention to prevent, limit, and control cholera outbreaks Our new large-scale cGMP production facilities in Hyderabad and Bhubaneswar will significantly enhance our production and supply capabilities for this Oral Cholera Vaccine, advancing our efforts to combat cholera globally,” said Dr. Krishna Ella, Executive Chairman of Bharat Biotech.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.